Should Investors Be Concerned About This Pharmaceutical Giant's Latest Clinical Trial?

Drug companies are granted patents on new drugs they develop for a reason. The ups and downs Novo Nordisk (NYSE: NVO) experienced in 2025 highlight exactly why.The good news at the end of the year was that the FDA approved a pill form of the company's GLP-1 weight loss medication. The bad news was the failure of a trial to see if the same GLP-1 medication helped Alzheimer's patients.Are either of these events as good or bad as they seem?Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool